Stockreport

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi [Yahoo! Finance]

Jaguar Health, Inc.  (JAGX) 
US:NASDAQ Investor Relations: jaguarhealth.gcs-web.com/investor-overview
PDF has the potential to provide Jaguar up to an additional $22M with milestones and other potential future payments Near-term milestones for intestinal failure program bu [Read more]